Clinical trials: Sintilimab
Colorectal Cancer, Immunotherapy
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
This study is intended to evaluate efficacy and safety of the combination of regorafenib and nivolumab as third-line or later therapy in patients with microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT04110093
- Testing
- Regorafenib and PD-1 inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Changzheng Hospital
Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the neoadjuvant therapy efficacy of IBI110 in combination with sintilimab versus sintilimab alone based on pathologic complete response (pCR) rate in stage IIB (primary tumor > 4 cm )…
- Trial name
- NCT05088967
- Testing
- IBI110, sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal…
- Trial name
- NCT07643623
- Testing
- tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab, Ipilimumab N01
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
The RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1).
- Trial name
- RADIANCE (NCT07756190)
- Testing
- Sintilimab, ipilimumab, Radscopal Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Anti-PD1 Antibody
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC.
- Conditions
- Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
- Trial name
- NCT04627012
- Testing
- Lenvatinib, Opdivo, Camrelizumab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited
Stage IIIC Gastric Cancer
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
In this study, we combine Nab-PTX, S-1 and sintilimab as adjuvant regimen to patients with stage IIIC GC. We are aiming to investigate the recommended dose of this regimen in a phase I study and estimate the toxicity and efficacy…
- Trial name
- NCT04781413
- Testing
- Nab-PTX, Sintilimab, S-1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Ruijin Hospital
Cholangiocarcinoma
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
- Trial name
- NCT05348811
- Testing
- HAIC combined with donafenib and sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhongda Hospital
Resectable Non-small Cell Lung Cancer
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
This study uses a prospective cohort design.Subjects are randomly divided into three groups (A, B, C) before surgery. Group A gets 3 cycles of sintilimab + chemo, Group B gets 2 cycles + 1 cycle, and Group C gets 1 cycle + 2…
- Trial name
- NCT06485557
- Testing
- sintilimab plus platinum-based chemotherapy
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Hepatocellular Carcinoma
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients.
- Trial name
- HAICPD1-HCC (NCT03869034)
- Testing
- HAIC+PD1, HAIC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
In 2018, global cancer incidence reached 18.1 million new cases, with 9.6 million cancer-related deaths. Colorectal cancer ranked as the third most common malignancy by incidence. Data from the U.S.
- Trial name
- NCT06776757
- Testing
- Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
NSCLC Stage IV, Brain Metastases
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab
- Conditions
- NSCLC Stage IV, Brain Metastases, SRS, Sintilimab
- Trial name
- NCT04180501
- Testing
- SRS sequential sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xiaorong Dong
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study
Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China, with most patients presenting with locally advanced disease.
- Trial name
- TTE-ESCC (NCT07778056)
- Testing
- Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
HCC - Hepatocellular Carcinoma
The DoHAICs Study Expansion Phase
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
- Trial name
- NCT07584018
- Testing
- Donafenib, sintilimab, HAIC
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colorectal Adenocarcinoma
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial.
- Trial name
- NCT05942768
- Testing
- regorafenib plus anti-PD-1 antibodies
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Hunan Cancer Hospital
Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
This study is an open-label, multicenter, single-arm clinical study.
- Conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation, PD-1 Antibody
- Trial name
- NCT07637448
- Testing
- EGFR-TKIs Combined with PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
This study aims to investigate the efficacy and safety of combining sintilimab and the TP regimen with/without IBI110 for neoadjuvant chemotherapy in resectable locally advanced head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT06494943
- Testing
- Sintilimab, IBI110, Paclitaxel
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Fudan University
Locally Advanced Rectal Cancer
Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer
This is a single arm, open-label, prospective phase II clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and immunotherapy (PD-1 antibody) for patients with locally advanced rectal cancer (LARC).
- Trial name
- NCT04663763
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Squamous Cell Non-small Cell Lung Cancer
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell…
- Trial name
- neoSCORE Ⅱ (NCT05429463)
- Testing
- Sintilimab, Carboplatin, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Elderly Patients, Metastatic Lung Cancer
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
Lung cancer is the cancer with the highest morbidity and mortality among men in the world. The proportion of elderly lung cancer patients in the global lung cancer population is steadily increasing, at the same time, it is also…
- Trial name
- NCT06032052
- Testing
- Single drug chemotherapy plus immunotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Hubei Cancer Hospital